• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酒精间隔消融术与外科室间隔切除术治疗梗阻性肥厚型心肌病现状的荟萃分析

A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.

作者信息

Singh Kuljit, Qutub Mohammad, Carson Kristin, Hibbert Benjamin, Glover Christopher

机构信息

Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, K1Y 1J7, Canada.

Department of Cardiology, Basil Hetzel Institution, University of Adelaide, SA, 5000, Australia.

出版信息

Catheter Cardiovasc Interv. 2016 Jul;88(1):107-15. doi: 10.1002/ccd.26293. Epub 2015 Nov 3.

DOI:10.1002/ccd.26293
PMID:26526299
Abstract

OBJECTIVE

Our objective was to perform an updated systematic review to compare the efficacy and short- and long-term mortality of surgical myectomy (SM) and alcohol septal ablation (ASA) by including most recent and largest cohort studies published in last few years.

BACKGROUND

SM and ASA are the two invasive strategies used to relieve left ventricular outflow tract obstruction (LVOTO) in patients with drug refractory symptomatic hypertrophic cardiomyopathy (HCM). In the absence of a randomized trial, we tried to compare the pros and cons of the two procedures using a systematic review and meta-analysis.

METHOD

A comprehensive search of three major databases was performed. We included original research studies comparing data on ASA and SM. Of 1,143 citations, 10 studies were included in the analysis.

RESULTS

A total of 805 patients underwent ASA and 1,019 underwent SM. Patients undergoing SM were younger (MD 6.3, P = 0.0001) and had higher reduction in the LVOT gradient (MD -9.56, P = 0.05). However, there was similar resolution of class III and IV symptoms between the two groups (P = 0.56). There was no difference in sudden cardiac death (SCD) (P = 0.93), short-term (P = 0.36), long-term all cause (P = 0.27), and long-term cardiac mortality (P = 0.58). Patients undergoing ASA had higher incidence of post procedure device implantation (OR 3.09, P < 0.00001).

CONCLUSION

No significant difference in symptom relief was noted between the two approaches. ASA was as safe a myectomy with regards to SCD, short-term, and long-term mortality. © 2015 Wiley Periodicals, Inc.

摘要

目的

我们的目的是进行一项更新的系统评价,通过纳入最近几年发表的最新且规模最大的队列研究,比较手术性室间隔心肌切除术(SM)和酒精室间隔消融术(ASA)的疗效以及短期和长期死亡率。

背景

SM和ASA是用于缓解药物难治性症状性肥厚型心肌病(HCM)患者左心室流出道梗阻(LVOTO)的两种侵入性治疗策略。在缺乏随机试验的情况下,我们试图通过系统评价和荟萃分析来比较这两种手术的利弊。

方法

对三个主要数据库进行了全面检索。我们纳入了比较ASA和SM数据的原始研究。在1143篇文献中,有10项研究纳入了分析。

结果

共有805例患者接受了ASA,1019例接受了SM。接受SM的患者更年轻(平均差值6.3,P = 0.0001),左心室流出道压差降低幅度更大(平均差值-9.56,P = 0.05)。然而,两组III级和IV级症状的缓解情况相似(P = 0.56)。心源性猝死(SCD)(P = 0.93)、短期(P = 0.36)、长期全因(P = 0.27)和长期心脏死亡率(P = 0.58)方面无差异。接受ASA的患者术后器械植入发生率更高(比值比3.09,P < 0.00001)。

结论

两种方法在症状缓解方面无显著差异。就SCD、短期和长期死亡率而言,ASA与心肌切除术一样安全。© 2015威利期刊公司

相似文献

1
A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy.酒精间隔消融术与外科室间隔切除术治疗梗阻性肥厚型心肌病现状的荟萃分析
Catheter Cardiovasc Interv. 2016 Jul;88(1):107-15. doi: 10.1002/ccd.26293. Epub 2015 Nov 3.
2
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.酒精间隔消融术治疗肥厚型梗阻性心肌病:已发表研究的系统评价
J Interv Cardiol. 2006 Aug;19(4):319-27. doi: 10.1111/j.1540-8183.2006.00153.x.
3
Gender-Based Outcome Discrepancies in Patients Who Underwent Alcohol Septal Ablation or Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.性别对接受酒精室间隔消融术或室间隔切除术治疗肥厚型梗阻性心肌病患者结局的影响:系统评价和荟萃分析。
Am J Cardiol. 2023 Dec 1;208:134-142. doi: 10.1016/j.amjcard.2023.09.033. Epub 2023 Oct 13.
4
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.药物难治性或药物不耐受性肥厚型心肌病的起搏治疗
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008523. doi: 10.1002/14651858.CD008523.pub2.
5
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.马伐卡坦治疗524例肥厚型心肌病国际队列患者疗效和安全性的系统评价与荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19.
6
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗:系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
7
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.早期或极早期肝细胞癌患者的管理:一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.
10
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.

引用本文的文献

1
What are the best clinical management strategies for cardiomyopathy? an umbrella review of systematic reviews and meta-analyses.心肌病的最佳临床管理策略有哪些?系统评价和荟萃分析的综合综述。
Front Pharmacol. 2025 Jul 25;16:1544121. doi: 10.3389/fphar.2025.1544121. eCollection 2025.
2
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.《2024年墨西哥肥厚型心肌病诊断与治疗指南》
Arch Cardiol Mex. 2024;94(Supl 4):1-75. doi: 10.24875/ACM.M25000098.
3
Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.
梗阻性肥厚型心肌病:从基因洞察到马伐卡坦、阿非卡坦及其他药物的多模式治疗方法
Egypt Heart J. 2024 Dec 7;76(1):156. doi: 10.1186/s43044-024-00587-y.
4
Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.奥地利肥厚型心肌病诊断与管理共识声明
Wien Klin Wochenschr. 2024 Oct;136(Suppl 15):571-597. doi: 10.1007/s00508-024-02442-1. Epub 2024 Oct 1.
5
The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy.肥厚型心肌病患者酒精室间隔消融术与室间隔心肌切除术中心室心律失常的风险:一项关于室间隔减容治疗的荟萃分析
Rev Cardiovasc Med. 2022 Nov 30;23(12):391. doi: 10.31083/j.rcm2312391. eCollection 2022 Dec.
6
Healthcare Professionals' Knowledge, Attitudes, and Practices in the Assessment, and Management of Sickle-Cell Disease: A Meta-Aggregative Review.医疗保健专业人员在镰状细胞病评估与管理中的知识、态度和实践:一项元聚合综述
Diseases. 2024 Jul 14;12(7):156. doi: 10.3390/diseases12070156.
7
Alcohol Septal Ablation for Hypertrophic Cardiomyopathy Guided by Intracoronary Myocardial Contrast Echocardiography to Reduce Myocardial Damage.冠状动脉内心肌对比超声心动图引导下的酒精间隔消融术治疗肥厚型心肌病以减少心肌损伤
J Med Ultrasound. 2023 Feb 13;32(2):170-172. doi: 10.4103/jmu.jmu_101_22. eCollection 2024 Apr-Jun.
8
Mortality After Alcohol Septal Ablation vs. Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy.酒精间隔消融术与间隔心肌切除术治疗梗阻性肥厚型心肌病患者后的死亡率比较
Circ Rep. 2024 Feb 21;6(3):74-79. doi: 10.1253/circrep.CR-23-0101. eCollection 2024 Mar 8.
9
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy.酒精间隔消融术或马伐卡坦治疗梗阻性肥厚型心肌病
J Clin Med. 2023 Oct 19;12(20):6628. doi: 10.3390/jcm12206628.
10
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy and bilateral lung transplantation for idiopathic pulmonary fibrosis: a case report.酒精间隔消融术治疗肥厚型梗阻性心肌病及特发性肺纤维化的双侧肺移植:一例报告
Eur Heart J Case Rep. 2023 Sep 19;7(9):ytad462. doi: 10.1093/ehjcr/ytad462. eCollection 2023 Sep.